COVID-19 Drug Given Via Inhaler Shows Promising Results


Trial of Covid-19 drug given via inhaler ‘very promising’, say scientists

by Niola Davis/the Guardian

Trials of an experimental drug inhaled by patients have found a significant reduction in hospital patients with Covid-19 needing to be put on a ventilator or dying from the disease, according to researchers

The drug, called SNG001, is delivered via an inhaler and is based on interferon beta, a protein produced naturally in the body that plays an important role in coordinating the body’s antiviral response.

Researchers have announced the results of an initial trial which found the odds of Covid-19 patients needing ventilation, or dying, while being treated in hospital were reduced by 79% among those given SNG001 compared with those given a placebo.

What is more, the team behind the trial say those given the drug were just over twice as likely to show “no limitation of activities” or “no clinical or virological evidence of infection” during the 16-day study period – in other words, the chance of recovery was boosted. Those given the drug also showed a reduction in breathlessness.

Read More:

Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy